Literature DB >> 29390582

A Klebsiella pneumoniae liver abscess presenting with myasthenia and tea-colored urine: A case report and review of 77 cases of bacterial rhabdomyolysis.

Lihua Deng1, Rong Jia, Wei Li, Qian Xue, Jie Liu, Yide Miao, Jingtong Wang.   

Abstract

RATIONALE: Rhabdomyolysis is a well-known syndrome in clinical practice, although rhabdomyolysis caused by a liver abscess is rarely reported and the patient may lack symptoms that are associated with a primary site of infection. Early recognition of this possibility is needed to avoid diagnostic delay and facilitate treatment. We report the case of a 71-year-old woman with a Klebsiella pneumoniae (KP) pyogenic liver abscess who presented with myasthenia and tea-colored urine and also review the 77 reported cases of bacterial rhabdomyolysis. PATIENT CONCERNS: The patient was 71 years old and presenting with a 7-day history of myasthenia and a 3-day history of tea-colored urine, but without fever or abdominal pain. DIAGNOSES: Laboratory testing in our case revealed rhabdomyolysis, and blood culture revealed KP. Abdominal ultrasonography revealed a hypoechoic enclosed mass, and computed tomography (CT) revealed an enclosed low-density mass (8.3 × 6.6 × 6.1 cm). The main diagnoses were a pyogenic liver abscess with rhabdomyolysis.
INTERVENTIONS: Empirically intravenous piperacillin-sulbactam and intravenous potassium treatment, as well as fluid infusions and other supportive treatments were provided after admission. After the diagnosis was confirmed and susceptibility test results were available, we adjusted the antibiotics to cefoperazone and sulbactam, which were maintained for 6 weeks. OUTCOMES: The patient's symptoms relieved and the abnormal laboratory parameters corrected. Follow-up abdominal ultrasonography at 24 months after her discharge revealed that the abscess had disappeared. LESSONS: Early recognition and careful consideration of the underlying cause of rhabdomyolysis are critical to improving the patient's prognosis. Thus, physicians should carefully consider the underlying cause in elderly patients who present with rhabdomyolysis, as they may lack symptoms of a primary infection.
Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29390582      PMCID: PMC5758284          DOI: 10.1097/MD.0000000000009458

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Case report

The patient approved the publication of this report. A 71-year-old woman with a 7-day history of myasthenia and a 3-day history of tea-colored urine, but without fever or abdominal pain, was admitted to our ward on December 1, 2014. She had hypertension, diabetes mellitus, and hyperlipidemia, which had been treated using nifedipine, repaglinide, metformin, and atorvastatin. No herbal supplements or herbal teas were used. The patient did not have a history of strenuous exercise. A physical examination at the admission revealed a temperature of 38.2°C, which increased to 39.5°C during the same day, as well as percussion-related pain in the hepatic region and muscle weakness in both legs. Laboratory testing revealed leukocytosis (white blood cell (WBC) was 12.97 × 109/L, 94.33% neutrophils), newly emerged severe thrombocytopenia (platelet (PLT) of 27.2 × 109/L), and the urine blood test (dry-chemistry method) was strongly positive without complete red blood cells or WBCs. The serum potassium level was 3.12 mmol/L, the serum creatine kinase (CK) level was significantly elevated (6020 IU/L), and the blood and urine were positive for myohemoglobin (2396.3 and 275.4 ng/mL, respectively). Her C-reactive protein level was 195 mg/L, her procalcitonin level was 3.34 ng/mL, and her glycosylated hemoglobin level was 7.1%. A blood culture from the admission revealed KP. Her serum creatinine level was normal and no findings were observed during screening for cerebrovascular disease, autoimmune disease, hemolytic disease, or altered thyroid function. Negative results were observed from testing for influenza A and B viruses, as well as for antibodies to Mycoplasma and Chlamydia. Abdominal ultrasonography revealed a hypoechoic mass in the S6 segment of the liver, and abdominal CT (Fig. 1A and B) revealed an enclosed low-density mass in the liver (8.3 cm × 6.6 cm × 6.1 cm), which suggested a liver abscess. Based on these findings, the diagnoses were a pyogenic liver abscess with hypokalemia and rhabdomyolysis. After admission, we empirically provided intravenous piperacillin–sulbactam (2.5 g every 8 hours) for 6 days before the blood culture results were available. Intravenous potassium treatment (9 g/day) was also administered for 4 days before the serum potassium level returned to normal, as well as fluid infusions (2.5–3 L/day) and other supportive treatments. After the diagnosis was confirmed and susceptibility test results were available, we adjusted the antibiotics to cefoperazone and sulbactam (3 g twice per day), which were maintained for 6 weeks. This was because the abscess was large and the patient and her family refused puncture and placement of a drainage tube. The patient's body temperature, CK level, and myohemoglobin levels in the urine and blood subsequently returned to normal (Supplementary Fig. 1). Abdominal ultrasonography at 24 months after discharge revealed that the abscess had disappeared (Fig. 1C).
Figure 1

Plain (A) and enhanced (B) abdominal computed tomography revealed an enclosed plurilocular mass. The walls and compartment of the mass exhibited enhancement, although the contents did not. Follow-up ultrasonography at 24 months revealed that the abscess had disappeared (C).

Plain (A) and enhanced (B) abdominal computed tomography revealed an enclosed plurilocular mass. The walls and compartment of the mass exhibited enhancement, although the contents did not. Follow-up ultrasonography at 24 months revealed that the abscess had disappeared (C).

Discussion

Liver abscess is a common type of visceral abscess that is caused by a bacterium, fungus, or amoeba. The estimated annual incidence of pyogenic liver abscess is approximately 2.3 cases per 100,000 population, and the incidence is higher among male patients.[ In China, pyogenic liver abscesses are predominantly caused by KP (77.1% of all cases),[ although liver abscesses presenting with myasthenia and tea-colored urine (indicative of rhabdomyolysis) are rare. To the best of our knowledge, there is only one English report describing a case of liver abscess-induced rhabdomyolysis. Rhabdomyolysis is a syndrome that results from separation of striated muscle fibers, which allows muscle enzymes, myoglobin, potassium, calcium, and other molecules to enter the circulation. Two previous studies have indicated that infectious rhabdomyolysis accounts for 5% to 31% of all cases.[ Our review of the 77 reported cases of bacterial rhabdomyolysis indicate that the most common organisms are Legionella spp., Streptococcus spp., and Salmonella spp. (Table 1),[ and that cases most frequently involve patients who are 40 to 50 years old (Fig. 2). The most common site of primary infection leading to rhabdomyolysis is the respiratory system (38–46.1% of all analyzed cases, Fig. 3),[ and the liver is rarely involved, with only one case of rhabdomyolysis caused by a liver abscess described in the English literature. That case involved Pantoea agglomerans (bolded in Table 1).[ Compared to noninfectious rhabdomyolysis, cases of infectious rhabdomyolysis tend to involve older patients (70.81 years old vs 55.31 years old) and more female patients (31.3% vs 9.3%), as well as significantly lower CK levels (3710.1 IU/L vs 19785.4 IU/L).[
Table 1

The 77 reported cases of bacterial rhabdomyolysis.

Figure 2

Age distribution for the 77 patients with bacterial rhabdomyolysis.

Figure 3

Distribution of the primary site of infection among 76 patients with bacterial rhabdomyolysis. Information regarding the primary site of infection was not available for 1 patient.

The 77 reported cases of bacterial rhabdomyolysis. Age distribution for the 77 patients with bacterial rhabdomyolysis. Distribution of the primary site of infection among 76 patients with bacterial rhabdomyolysis. Information regarding the primary site of infection was not available for 1 patient. Although complete CK data were not available for all reported cases, the CK level in the present case was relatively low (as a product of the rhabdomyolysis), which agrees with the previously reported data. In addition, our patient exhibited concurrent hypokalemia, which likely reflects an even lower serum potassium level before the rhabdomyolysis occurred. Serious hypokalemia can also cause rhabdomyolysis, although the patient did not have any related medical condition and responded well to potassium supplementation after the infection was controlled. Furthermore, studies have revealed a hypokalemia prevalence of 23% among hospitalized patients with infectious disease.[ Thus, we speculate that the hypokalemia might have been caused by infection and associated multiple organ dysfunction, which can be inferred from the Sequential Organ Failure Assessment score of 6 points at the admission. Moreover, her serum potassium levels normalized after treatment, and the hypokalemia might have contributed to the rhabdomyolysis. As medications are common causes of rhabdomyolysis, we investigated the patient's medications and observed that she had received nifedipine, repaglinide, metformin, and atorvastatin. A search of the literature (“nifedipine, rhabdomyolysis” and “repaglinide, rhabdomyolysis”) revealed no related cases or data. Although there are cases of metformin-induced rhabdomyolysis, they are typically associated with overdose.[ Interestingly, atorvastatin is the second most prescribed statin (24.4–36%),[ and the incidence of atorvastatin-induced myopathy is approximately 14.9%.[ However, the patient had discontinued atorvastatin for 1 month before the onset of rhabdomyolysis, and we are not aware of any delayed cases of atorvastatin-induced rhabdomyolysis. Thus, there is no evidence to indicate that our patient had drug-induced rhabdomyolysis. This case was diagnosed during the influenza season, and influenza can also present with myasthenia and fever, as well as be complicated by myositis or rhabdomyolysis.[ Thus, this possibility should be considered in similar cases. However, the patient denied being exposed to individuals with a fever, and no influenza A or B viruses were detected after her admission. Therefore, there is no evidence to indicate that influenza virus infection was involved in this case. In conclusion, elderly patients with a liver abscess may lack symptoms that are associated with a primary site, which can make it difficult to diagnose. However, this condition can cause serious complications, such as rhabdomyolysis. Thus, it is important to investigate the underlying cause in elderly patients with rhabdomyolysis, and to consider the possibility of a liver abscess.
  38 in total

1.  Salmonella infection-associated acute rhabdomyolysis. Some pathogenic considerations.

Authors:  Nada Brncic; Ivica Viskovic; Antun Sasso; Ivan Kraus; Gordana Zamolo
Journal:  Arch Med Res       Date:  2002 May-Jun       Impact factor: 2.235

2.  Rhabdomyolysis of infectious and noninfectious causes.

Authors:  José Ramón Blanco; Marta Zabalza; Javier Salcedo; Lorenzo Echeverria; Ana García; Manuel Vallejo
Journal:  South Med J       Date:  2002-05       Impact factor: 0.954

3.  Rhabdomyolysis, acute renal failure and Legionnaires' disease.

Authors:  F Brivet; T Pham Van; P Petitpretz; J F Delfraissy
Journal:  Chest       Date:  1984-12       Impact factor: 9.410

4.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

5.  The prevalence of hypokalemia in hospitalized patients with infectious diseases problem at Cipto Mangunkusumo Hospital, Jakarta.

Authors:  Djoko Widodo; Budi Setiawan; Khie Chen; Leonard Nainggolan; Widayat Djoko Santoso
Journal:  Acta Med Indones       Date:  2006 Oct-Dec

6.  Comparison of pyogenic liver abscesses caused by hypermucoviscous Klebsiella pneumoniae and non-Klebsiella pneumoniae pathogens in Beijing: a retrospective analysis.

Authors:  Jing Wang; Yan Yan; Xinying Xue; Kaifei Wang; Dingxia Shen
Journal:  J Int Med Res       Date:  2013-05-31       Impact factor: 1.671

7.  Pantoea agglomerans liver abscess presenting with a painful thigh.

Authors:  Duncan G Fullerton; Aye A Lwin; Simon Lal
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 2.566

8.  Tularemia and rhabdomyolysis.

Authors:  A B Kaiser; D Rieves; A H Price; M R Gelfand; R E Parrish; M D Decker; M E Evans
Journal:  JAMA       Date:  1985-01-11       Impact factor: 56.272

9.  Pneumococcal cellulitis.

Authors:  M Dhaene; J P Thys; R Askenasi; C Toussaint
Journal:  Am J Emerg Med       Date:  1986-05       Impact factor: 2.469

10.  Gastroenteritis, fever and myoglobinuric renal failure.

Authors:  D Simcock
Journal:  J R Soc Med       Date:  2004-04       Impact factor: 18.000

View more
  3 in total

1.  Treatment of pyogenic liver abscess by surgical incision and drainage combined with platelet-rich plasma: A case report.

Authors:  Jun-Hong Wang; Zhen-Hua Gao; Hong-Liang Qian; Jin-Shun Li; Hao-Min Ji; Ming-Xu Da
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

2.  Rhabdomyolysis-induced acute kidney injury in a patient with undifferentiated connective tissue disease: A case report and literature review rhabdomyolysis-induced AKI in a patient with UCTD.

Authors:  Hongxia Mai; Yuliang Zhao; Stephen Salerno; Yi Li; Letian Yang; Ping Fu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Pyogenic Liver Abscess with No Predisposing Risk Factors.

Authors:  Matthew Chadwick; Leonid Shamban; Michael Neumann
Journal:  Case Rep Gastrointest Med       Date:  2018-09-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.